| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
3,940,000 |
| Market
Cap: |
1.08(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.275 - $0.275 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile NanoVibronix is a medical device company that focuses on noninvasive biological response-activating devices that target biofilm prevention, wound healing and pain therapy and can be administered at home, without the assistance of medical personnel. Co.'s primary products, which are in various stages of clinical and market development, consist of: UroShield™, which is an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy and decrease pain and discomfort associated with urinary catheter use; and PainShield™, which is a patch-based therapeutic ultrasound technology to treat pain, muscle spasm and joint contractures.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
92,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$37,708 |
| Total People Bought |
0 |
0 |
0 |
3 |
| Total Buy Transactions |
0 |
0 |
0 |
3 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Mika Thomas |
Director |
– • – |
2023-01-05 |
4 |
B |
$0.25 |
$12,500 |
D/D |
50,000 |
50,000 |
2.39 |
4% |
|
| Fashek Christopher M |
Director |
– • – |
2022-06-15 |
4 |
B |
$0.60 |
$23,828 |
D/D |
40,000 |
75,000 |
2.39 |
-29% |
|
| Cassirer Aurora |
Director |
– • – |
2022-06-01 |
4 |
B |
$0.69 |
$1,380 |
D/D |
2,000 |
2,000 |
2.31 |
-37% |
|
| Fashek Christopher M |
Director |
– • – |
2020-09-29 |
4 |
B |
$0.79 |
$7,887 |
D/D |
10,000 |
10,000 |
2.39 |
110% |
|
| Fashek Christopher M |
Director |
– • – |
2019-11-20 |
4 |
B |
$2.00 |
$50,000 |
D/D |
25,000 |
25,000 |
2.39 |
- |
|
| Kelly Miriam W |
10% Owner |
– – • |
2015-04-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
215,355 |
|
- |
|
| Jacob Harold |
Chief Medical OfficerOfficer |
• • – |
2015-04-10 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
64,178 |
|
- |
|
| Jacob Harold |
Chief Medical OfficerOfficer |
• • – |
2015-04-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
25,662 |
|
- |
|
| Greenstein Ira A |
Director |
– • – |
2015-04-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
59,130 |
|
- |
|
| Zumeris Jona |
VP of TechnologyOfficer |
• • – |
2015-04-10 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
68,879 |
|
- |
|
10 Records found
|
1
|
Page 1 of 1 |
|
|
